Table 3.

Adverse events that were at least possibly due to treatment in at least 10 % of patients

Adverse event (N = 68)	Grades 1 or 2		Grade 3		Grade 4		Any grade
	No. of patients	%	No. of patients	%	No. of patients	%	No. of patients	%
Hematologic
Neutropenia	15	22	13	19	8	12	36	53
Anemia	47	69	5	7	0	0	52	76
Thrombocytopenia	30	44	4	6	2	3	36	53
Infection	2	3	0	0	0	0	2	3
Gastrointestinal
Nausea	36	53	8	12	0	0	44	65
Vomiting	15	22	8	12	0	0	23	34
Diarrhea	26	38	6	9	0	0	32	47
Dehydration	10	15	1	1	0	0	11	16
Constipation	10	15	1	1	0	0	11	16
Abdominal pain	10	15	2	3	0	0	12	18
Constitutional
Anorexia	25	37	6	9	0	0	31	46
Fatigue	38	56	5	7	0	0	43	63
Weight loss	11	16	0	0	0	0	11	16
Metabolic
Hypokalemia	24	35	3	4	0	0	27	39
Hyponatremia	6	9	2	3	0	0	8	12
ALT, SGPT	19	28	0	0	0	0	19	28
AST, SGOT	27	40	0	0	0	0	27	40
Bilirubin	12	18	1	1	0	0	13	19
Neurologic
Neuropathy, sensory	20	29	3	4	0	0	23	33
Dizziness	10	15	0	0	0	0	10	15
Insomnia	7	10	0	0	0	0	7	10
Pulmonary
Dyspnea	10	15	0	0	1	1	11	16
Skin
Hand–foot reaction	27	40	5	7	0	0	32	47
Rash/desquamation	15	22	1	1	0	0	16	23